Health Care · Biotechnology · US stock · price as of 16 Oct 2026
Key indicators
Price
$285.42
52-week range
$188.25 – $291.40
Market cap
$505.5B
P/E (trailing)
80.2×
EV / EBITDA
33.8×
Free-cash-flow yield
3.6%
Dividend yield
2.4%
Revenue (last 12 months)
$64.4B
Revenue growth (3y a year)
1.8%
Operating margin
26.2%
Return on invested capital
21.0%
Net debt / EBITDA
3.8×
Fair value
Blended fair value$141.53 range $135 – $148
Versus priceOvervalued−50% to fair value
Peer multiples
$195.95
Fundamentals-adjusted multiple
$125.62
10-year DCF (market-scaled)
$103.03
Earnings power value (floor, not blended)
$35.18
Model uncertainty
Medium
X-Ray Score
41/ 100 · High confidence · ahead of 22% of sector peers
Valuation23
Growth35
Profitability66
Financial health29
Dividends53
Five-year price chart navy: price · brown: 200-day average · blue band: fair value range
Executive summary
AbbVie is a research-based biopharmaceutical company. Its medicines treat conditions in immunology, oncology, neuroscience and eye care, and its aesthetics business includes Botox. Skyrizi, Rinvoq and Humira are among its major immunology products. Customers are wholesalers, pharmacies, hospitals and health systems, which in turn supply patients, and the company operates globally with a heavy emphasis on research and development.
AbbVie earns money from prescription medicines and aesthetics products, which are protected for periods by patents. Revenue is $64.4 billion over the last twelve months, with revenue growth over three years of 1.8% a year. The operating margin is 26.2%, and the business earns a profit of 21% on the capital invested in it. It has net debt of 3.8 times EBITDA, and the dividend yield is 2.4%.
StocksXray gives AbbVie Inc. an X-Ray Score of 41 out of 100 (high confidence), ahead of 22% of the S&P 500 stocks in its sector. Its strongest lens is profitability (66) and its weakest is valuation (23).
Our fair value blend is $141.53 (range $134.84 to $147.59). At $285.42 the stock trades 102% above that blend, so the label is "Overvalued" with medium model uncertainty. Fair value is a range, not a price target.
XStocksXray
AbbVie Inc. (ABBV)
Valuation history multiples at each fiscal year-end price; the last column uses today's price and the last twelve months
FY2021
FY2022
FY2023
FY2024
FY2025
Now
Price
$113.37
$140.59
$140.26
$166.71
$221.85
$285.42
Market cap
$201.5B
$250.0B
$248.7B
$295.6B
$393.3B
$505.5B
P/E
17.6×
21.2×
51.6×
69.8×
94.0×
80.2×
EV / revenue
4.8×
5.2×
5.4×
6.3×
7.4×
8.8×
EV / EBITDA
15.0×
16.8×
23.1×
39.1×
30.2×
33.8×
Price / free cash flow
9.2×
10.3×
11.3×
16.6×
22.1×
27.8×
Free-cash-flow yield
10.9%
9.7%
8.9%
6.0%
4.5%
3.6%
Price / book
13.1×
14.5×
24.0×
88.9×
–
–
Dividend yield
4.68%
4.06%
4.27%
3.77%
3.00%
2.42%
Fundamentals checklist ● 4 Good · ● 4 Average · ● 8 Bad · each check graded against the sector
Cash quality
Earnings backed by cash−9.8%Good
Free-cash-flow yield3.6%Average
Risk models
Altman Z score0.0×Bad
Piotroski F-Score7 of 9Average
Growth
EPS growth (3y)−29.1%Bad
Free-cash-flow growth (3y)−9.8%Bad
Revenue growth (3y)1.8%Bad
Growth consistency100%Good
Balance sheet
Current ratio0.8×Bad
Net debt / EBITDA3.8×Bad
Interest cover5.8×Average
Valuation
Fair value vs price0.5×Bad
EBIT / EV yield3.0%Bad
Profitability
Return on invested capital21.0%Good
Operating margin26.2%Good
Gross profitability34.1%Average
Red flags
Negative equity — Book equity is negative
XStocksXray
AbbVie Inc. (ABBV)
Financials US$ millions, from SEC filings; last column is the last twelve months
Income statement
FY21
FY22
FY23
FY24
FY25
LTM
Revenue
56,197
58,054
54,318
56,334
61,160
64,386
Gross profit
38,751
40,640
33,903
39,430
42,956
46,021
Operating income
17,924
18,117
12,757
9,137
15,075
16,870
Net income
11,542
11,836
4,863
4,278
4,226
6,310
Diluted EPS ($)
6.45
6.63
2.72
2.39
2.36
3.56
Free cash flow
21,990
24,248
22,062
17,832
17,816
18,210
Gross margin
69.0%
70.0%
62.4%
70.0%
70.2%
71.5%
Operating margin
31.9%
31.2%
23.5%
16.2%
24.6%
26.2%
Net margin
20.5%
20.4%
9.0%
7.6%
6.9%
9.8%
Balance sheet
FY21
FY22
FY23
FY24
FY25
LTM
Total assets
146,529
138,805
134,711
135,161
133,960
135,115
Cash
9,746
9,201
12,814
5,524
5,229
6,569
Total debt
76,684
63,271
59,385
67,144
67,496
70,822
Equity
15,408
17,254
10,360
3,325
-3,270
-5,935
Dividend per share ($)
5.31
5.71
5.99
6.29
6.65
6.83
Revenue and net income US$ billions: navy revenue, teal net income
Every number comes from SEC filings, end-of-day prices and the StocksXray models described on the methodology page. The X-Ray Score ranks each metric against the company's own sector. Fair value blends three models and carries a typical error of about 40%, so treat it as a range. Analyst ratings, price targets and earnings-call summaries are not part of this report. Educational research, not financial advice; read the disclaimer.